Market Assessment, Breast Cancer, Non Small Cell Lung Cancer, Ovarian Cancer Access and Reimbursement Realizing the Potential of Personalized Medicine in Oncology US 2016 Report

Biomarker-driven prescribing plays an increasingly prominent role in key oncology indications. The choice of therapy for breast cancer has long been informed by the presence of key biomarkers, and EGFR and ALK status are well-established markers for determining treatment in non-small-cell lung cancer (NSCLC). Treatment of ovarian cancer has only recently begun to benefit from this trend, but the role of biomarkers will continue to evolve in all three indications.

Back to all Market Assessment reports

Contact us

Investors

Careers

Login

Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer | Access and Reimbursement | Realizing the Potential of Personalized Medicine in Oncology | US | 2016

Related Market Assessment Reports

Urticaria – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Chronic Inducible Urticaria (US) 2023

Myasthenia Gravis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

Ulcerative Colitis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Adult (US)

Asthma | Unmet Need | Severe Asthma | US/EU | 2021

Asthma – Unmet Need – Detailed, Expanded Analysis – Severe Asthma (US/EU)